CT-P17

CT-P17 is a biosimilar medication that closely resembles the biological drug Stelara (ustekinumab). It is used to treat conditions like psoriasis and Crohn’s disease by targeting specific parts of the immune system involved in inflammation. Being a biosimilar means it offers a similar safety, effectiveness, and quality profile to the original drug but may be available at a lower cost. CT-P17 provides an additional treatment option for patients and healthcare providers, expanding access to biologic therapies while maintaining the benefits of the established medication.